BigOmics Analytics, a spin-off of the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+) and Dalle Molle Institute for Artificial Intelligence (IDSIA, joint institute of USI and SUPSI), announces raising additional funding from Eppendorf, a leading life science company that develops and sells instruments, consumables and services for liquid, sample and cell handling in laboratories worldwide. The additional funding brings the total amount raised so far to CHF 2.7M. It will be used to further develop BigOmics’ platforms, to expand its team and to grow its presence in the market.
BigOmics is a Swiss data analytics startup with the vision of democratizing biodata analysis in digital healthcare to accelerate scientific discoveries in medicine. The analysis of biodata represents a major bottleneck in current life science research. BigOmics enables biologists to analyze omics data with maximum ease thanks to their intelligent self-service analysis software.
BigOmics was founded in 2018 by Ivo Kwee and Murodzhon Akhmedov as a spin-off of the Institute of Oncology Research (IOR, affiliated to Universitą della Svizzera italiana) and the Dalle Molle Institute for Artificial Intelligence (IDSIA, joint institute of USI and SUPSI). The startup currently employs four former USI students/employees and is currently hosted at the USI Startup Centre in Lugano.
IDSIA is a research institute for artificial intelligence, affiliated with both the University of Lugano and SUPSI. It focuses on machine learning (artificial neural networks, reinforcement learning), optimal universal artificial intelligence and optimal rational agents, operations research, complexity theory, environmental modeling and software and robotics.
Read the full press release: https://bigomics.ch/2022/03/17/bigomics-closes-pre-series-a-with-additional-investment-from-eppendorf/